HYORTH

This brand name is authorized in Nigeria.

Active ingredients

The drug HYORTH contains one active pharmaceutical ingredient (API):

1	Hyaluronate sodium UNII YSE9PPT4TH - HYALURONATE SODIUM
	Read more about Hyaluronate sodium

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
B4-7863	Injection	HYORTH XL INJECTION INJ 8mg; 0.16mg; 0.04mg; 8.5mg 16ML	HYORTH XL INJECTION SODIUM HYALURONATE BP 8MG, SODIUM HYALURONATE BP 8MG, DI SODIUM HYDROGEN PHOSPHATE DIHYDRATE 0.16MG, MONOSODIUM PHOSPHATE MONOHYDRATE 0.04MG, SODIUM CHLORIDE 8.5MG, WATER FOR INJECTION B4-7863 Drugs Imported Products 16ML 02/12/2022 SJS LIFE SCIENCES LIMITED, 11, OLU AKERELE STREET IKEJA LAGOS 8020347702 sjslifesciencesltd@gmail.com VIRCHOW BIOTECH PVT LTD, Survey 172, part-Gagilapur Village, Outbulapur, Mandel Ronger Reddy Dist-Ardna, Prodesh, India., India	26/04/2023
C4-0248	Injection	HYORTH INJECTION INJ 20 mg/2 mL 1 X 2ml	97 RNW-PP-361586 HYORTH INJECTION SODIUM HYALURONATE STERILE SOLUTION 20 MG/2 ML Sodium Hyaluronate Sterile solution 20 mg/2 ml, Sodium chloride, Di-Sodium Hydrogen Phosphate dehydrate, Monosodium phosphate monohydrate, Water for Injection C4-0248 Drugs Imported Products 12ML POM 1 9/15/2023 SJS LIFE SCIENCES LIMITED, 11, OLU AKERELE STREET, IKEJA, LAGOS 8114441430 sjslifesciencesltd@gmail.com VIRCHOW BIOTECH PRIVATE LIMITED, NO. 172 PART, GAGILLAPUR, QUTUBULLAPUR, R.R. DISTRICT -500 043, TELANGANA. INDIA., India	30/11/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
M09AX01	Hyaluronic acid	M Musculo-skeletal system → M09 Other drugs for disorders of the musculo-skeletal system → M09A Other drugs for disorders of the musculo-skeletal system → M09AX Other drugs for disorders of the musculo-skeletal system
Discover more medicines within M09AX01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	B4-7863, C4-0248